Rasio rega marang prakiraan pendapatan Benitec Biopharma (BNTC)
The forward price-to-sales valuation reflects the cost dynamics of Benitec Biopharma Inc. (BNTC), where the 8841.90 mark serves as the current indicator. Benitec Biopharma Inc. (BNTC) utilizes RNA interference to block pathogenic genes and treat rare diseases. The production cycle relies on contract manufacturing organizations (CMO) supported by in-house R&D centers. Current management success and market capitalization depend on the outcomes of gene therapy clinical trials.
Rincian metrik lan analitis perusahaan Benitec Corp (BNTC)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Total Utang marang Modal Benitec Biopharma Inc.|BNTC - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Benitec Biopharma Inc.|BNTC - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Benitec Corp|BNTC - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Benitec Biopharma|Indikator likuiditas cepet benitec.com
- data bathi bisnis lan rasio investasi:
BNTC - Bathi pungkasan|Proyeksi bathi mangsa ngarep Benitec Biopharma Inc.|BNTC - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Benitec|BNTC - Rasio P/E diaturake wutah|Pangali EV/EBITDA Benitec Corp|BNTC - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Benitec Biopharma|BNTC - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan benitec.com|BNTC - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Benitec Biopharma Inc.
- informasi babagan volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:BNTC (Benitec Biopharma)
For Benitec Biopharma Inc. (BNTC), which is developing breakthrough ddRNAi technology for the treatment of rare diseases, the expected P/S metric serves as a tool to verify market value relative to projected revenue. Comparing market capitalization with future sales allows investors to filter out speculative noise, revealing whether the company's assets are truly overvalued or undervalued during the clinical trial stage before actual financial results are realized.
Pesaing Benitec Biopharma Inc. (BNTC)
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Repligen Inc.|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CRSP (crisprtx.com)|WGS (GeneDx) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator Forward P/S BEAM|Multiplikator Forward P/S Sarepta Corp (SRPT)|Rasio rega marang prakiraan pendapatan Twist Bioscience TWST|Rega forward marang dodolan TXG|NTLA - Rasio rega marang prakiraan pendapatan|Stoke Therapeutics Inc (STOK) - Multiplikator forward rega marang pendapatan|BLFS: Multiplikator Forward P/S|Wave Pharma (WVE) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan MAZE|SION: Rega forward marang dodolan|Multiplikator Forward P/S PRME|Rasio kapitalisasi marang dodolan sing dikarepake Taysha Gene Therapies Inc|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MGTX: Kapitalisasi marang prakiraan pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|solidbio.com (SLDB) - Multiplikator forward rega marang pendapatan|OCGN (Ocugen) - Multiplikator forward rega marang pendapatan|PACB - Rasio kapitalisasi marang dodolan sing dikarepake|DSGN (Design Pharma) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan RCKT|Rasio rega marang prakiraan pendapatan 4D Molecular Therapeutics (FDMT)|lexeotx.com - Kapitalisasi marang prakiraan pendapatan|Korro Bio - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake EDIT (Editas Medicine Inc)|Silence Therapeutics Inc. - Multiplikator Forward P/S|ProQR Therapeutics N.V. (PRQR) - Multiplikator forward rega marang pendapatan|CDXS: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan SGMO|Rasio rega marang prakiraan pendapatan Nautilus Biotechnology, Inc.|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Multiplikator Forward P/S DTIL|Multiplikator Forward P/S generationbio.com (GBIO)|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Exicure Inc. - Rasio rega marang prakiraan pendapatan|Celsion Corporation - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan RNAZ|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|adnas.com (APDN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan BLUE (bluebird bio)|Rasio rega marang pendapatan sing dikarepake IPA|Multiplikator Forward P/S OMGA (Omega)|Singular Genomics Corp (OMIC) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Regulus Therapeutics - Multiplikator Forward P/S|syros.com (SYRS) - Multiplikator forward rega marang pendapatan|TBIO (Telesis Bio) - Multiplikator forward rega marang pendapatan|TRACON Pharmaceuticals Inc. - Rega forward marang dodolan|UBX (Unity Bio) - Multiplikator Forward P/S
